NDA 202292 · Napo Pharms INC
Mytesi
Crofelemer · Oral · Antidiarrheal
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Apr 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 31, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
5 Phase 3, 1 recruiting
FAERS reports
239
84 serious, 29 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2026.
MYTESI is indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. MYTESI is an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. ( 1 )
Mechanism: Crofelemer is an inhibitor of both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl¯) channel, and the calcium-activated Cl¯ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl¯ channel and CaCC regulate Cl¯ and fluid secretion by intestinal epithelial cells. Crofelemer acts by blocking Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing the flow of Cl¯ and water in the gastrointestinal tract.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 31, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewLabel
1 products under this application
- MYTESI · CROFELEMER 125MG · TABLET, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Crofelemer" as an intervention, any sponsor and status, largest first.
Shaman PharmaceuticalsIndustry
NCT00002186 · 400 participants
Drug: Crofelemer; Acyclovir · For: Herpes Simplex; HIV Infections
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 34 sites in all
- Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated DiarrheaPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00547898 · 374 participants · Start Oct 2007 · Primary completion Jan 27, 2011
Drug: Crofelemer 125 mg; Crofelemer 250 mg and 2 more · For: HIV Associated Diarrhea
Sites: Huntsville, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 82 sites in all
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) PatientsPivotal-lookingCompleted
Shaman PharmaceuticalsIndustry
NCT00002408 · 300 participants
Drug: Crofelemer · For: Diarrhea; HIV Infections
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 36 sites in all
- Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyPivotal-lookingCompleted
Napo Pharmaceuticals, Inc.Industry
NCT04538625 · 287 participants · Start Oct 7, 2020 · Primary completion Aug 7, 2023
Drug: Crofelemer 125 MG [Mytesi]; Placebo · For: Cancer Therapy-Related Diarrhea; Chemotherapy-related Diarrhea; Adult Solid Tumor and 3 more
Sites: Prescott, Arizona; Anaheim, California; Corona, California · 52 sites in all
- Safety and Tolerability of Crofelemer for HIV-Associated DiarrheaPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01374490 · 250 participants · Start Jun 7, 2011 · Primary completion Oct 31, 2012
Drug: Crofelemer · For: HIV Enteropathy; Diarrhea With HIV
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bakersfield, California · 21 sites in all
- A Study of Crofelemer to Treat Diarrhea Irritable Bowel SyndromePivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00101725 · 245 participants · Start Dec 2004 · Primary completion Nov 2005
Drug: crofelemer · For: Irritable Bowel Syndrome; Colonic Diseases; Diarrhea and 1 more
Sites: Huntsville, Alabama; Chandler, Arizona; North Little Rock, Arkansas · 29 sites in all
- Diarrhea Predominant Irritable Bowel Syndrome in FemalesPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00461526 · 240 participants · Start Oct 2006 · Primary completion Dec 2007
Drug: crofelemer · For: Irritable Bowel Syndrome
Sites: Huntsville, Alabama; Chandler, Arizona; Tucson, Arizona · 43 sites in all
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03898856 · 93 participants · Start Apr 1, 2019 · Primary completion Jan 30, 2025
Drug: Crofelemer · For: Chronic Diarrhea of Unknown Origin
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use61
- drug ineffective51
- product dose omission issue29
- diarrhoea26
- death23
- pain17
- anxiety14
- emotional distress14
- anhedonia12
- fatigue11
- chronic kidney disease10
- dizziness10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 14 |
| 2022 | 39 |
| 2023 | 43 |
| 2024 | 46 |
| 2025 | 40 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mytesi (Crofelemer)
2024 spending
$8.0M
Beneficiaries
376
2,591 claims
Per beneficiary
$21,348
$41.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,432,051 |
| 2021 | $9,047,448 |
| 2022 | $7,379,846 |
| 2023 | $7,449,992 |
| 2024 | $8,026,902 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Jacob S, Johnson M, Roque B, et al. · Clin Breast Cancer 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
Nee J, Salley K, Ludwig AG, et al. · Clin Transl Gastroenterol 2019 · Clinical Trial, Phase II, Multicenter Study
- HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Pohlmann PR, Graham D, Wu T, et al. · Breast Cancer Res Treat 2022 · Randomized Controlled Trial, Clinical Trial, Phase II
- Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
Mangel AW, Chaturvedi P · Digestion 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
Macarthur RD, Hawkins TN, Brown SJ, et al. · HIV Clin Trials 2013 · Clinical Trial, Phase III, Multicenter Study
- Effect of crofelemer extract on severity and consistency of experimentally induced enterotoxigenic Escherichia coli diarrhea in newborn Holstein calves.
Teixeira AG, Stephens L, Divers TJ, et al. · J Dairy Sci 2015 · Randomized Controlled Trial
Sponsor: Napo Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.